Skip to Content

ASH 2023: CAPTIVATE Study – Ibrutinib-Venetoclax for CLL/SLL

The CAPTIVATE study’s latest findings offer new hope for CLL/SLL patients with the oral ibrutinib-venetoclax, demonstrating lasting remissions and promising retreatment outcomes.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top